drugset / Trial / NCT00282100
Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
Phase 2
Unknown
40 enrolled
Tan Tock Seng Hospital
AstraZeneca · collabSingapore Cancer Syndicate. · collab
NaSingle-groupOpen-labelPrevention
Summary
This research is being done to find how soon the liver cancer may come back and whether proteins or genes in tumor, blood or urine can give us clues of early recurrence.
Timeline
- Start
- 2005-12
- Primary completion
- 2019-09
- Completion
- 2019-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | Oral |